BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

...complex class II DQ8 MHCI-Major histocompatibility complex class I Jaime de León, Staff Writer IMT-002 VBY-129 ImmunoMolecular Therapeutics LLC Virobay Inc. Cathepsin S (CTSS) Major...
BioCentury | Dec 8, 2017
Financial News

Lumicell raises $28.7M series C, reports breast cancer detection data

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million on Dec. 7 in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed...
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio...
BioCentury | Dec 7, 2017
Financial News

Lumicell raises $28.7M series C, reports breast cancer detection data

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed investors. Lumicell said...
BioCentury | Oct 10, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A panel of 17 genomic loci could help predict the risk of PD. Genome-wide association studies in a total of 20,084 PD patients and 397,324 healthy volunteers identified associations between the disease...
BioCentury | Sep 29, 2017
Clinical News

Medivir reports Phase IIa data of MIV-711 for OA

Medivir AB (SSE:MVIR B) reported top-line data showing that MIV-711 slowed the degenerative effects of moderate osteoarthritis (OA) on both bone and cartilage of the knee in the Phase IIa MIV-711-201 trial. The company said...
BioCentury | Sep 26, 2017
Clinical News

Medivir rises on Phase IIa OA data

Medivir AB (SSE:MVIR B) gained SEK14.75 (25%) to SEK74.75 on Tuesday after reporting that MIV-711 slowed the degenerative effects of moderate osteoarthritis on both bone and cartilage of the knee in the Phase IIa MIV-711-201...
Items per page:
1 - 10 of 169